[Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]

Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8. doi: 10.1055/s-0032-1327244. Epub 2012 Nov 27.
[Article in German]


Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia, is with a prevalence of 2-29 cases per 100,000 individuals a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years. As in Europe data are limited on the characteristics and management of such patients, INSIGHTS-IPF was initiated as a new registry that documents incident and prevalent patients with confirmed IPF diagnosis prospectively. Detailed data on patient characteristics, diagnostics, management, clinical outcomes, quality of life and resource utilization are recorded. It is planned to document 500 patients in 30 centers. The registry will contribute to the optimization of the management of IPF patients in the long term.

Publication types

  • Comparative Study
  • English Abstract
  • Review

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Biopsy
  • Cross-Cultural Comparison
  • Cross-Sectional Studies
  • Female
  • Germany
  • Humans
  • Idiopathic Pulmonary Fibrosis / diagnosis*
  • Idiopathic Pulmonary Fibrosis / mortality
  • Idiopathic Pulmonary Fibrosis / pathology
  • Idiopathic Pulmonary Fibrosis / therapy*
  • Lung / pathology
  • Male
  • Prognosis
  • Prospective Studies
  • Pyridones / therapeutic use
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Rare Diseases
  • Registries*
  • Sex Factors
  • Survival Analysis
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Pyridones
  • pirfenidone